NCT01027260View on ClinicalTrials.gov

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

PHASE2CompletedINTERVENTIONAL
Enrollment

268

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Itopride HCI 50 mg

Variable dosing

DRUG

Itopride HCI 100 mg

Variable dosing

DRUG

Placebo

Variable dosing

Trial Locations (4)

74800

Site Reference ID/Investigator# 5870, Karachi

Unknown

Site Reference ID/Investigator# 21441, Karachi

Site Reference ID/Investigator# 6130, Lahore

Site Reference ID/Investigator# 8535, Rawalpindi

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY